Pipeline Overview
| Product | Mechanism | Ownership | Indication | Preclinical | Clinical Stage Phase 1/2 |
|---|---|---|---|---|---|
| Tuspetinib* | Myeloid Kinase | Aptose WW | AML |
complete
AML
Preclinical Phase complete
|
in progress
Clinical Stage Phase 1/2 Phase in progress
|
| Luxeptinib** | Lymphoid Kinase | Aptose: WW Crystal Genomics: Korea |
CLL & NHL |
complete
CLL & NHL
Preclinical Phase complete
|
in progress
Clinical Stage Phase 1/2 Phase in progress
|
| Luxeptinib** | Myeloid Kinase | Aptose: WW Crystal Genomics: Korea |
AML & MDS |
complete
AML & MDS
Preclinical Phase complete
|
in progress
Clinical Stage Phase 1/2 Phase in progress
|
| APTO-253 | MYC, KLF4 | Aptose: WW | AML & MDS |
complete
AML & MDS
Preclinical Phase complete
|
in progress
Clinical Stage Phase 1/2 Phase in progress
|
| APL-581 | BRD4/JAK | Aptose and Ohm | Hematologic Cancers |
in progress
Hematologic Cancers
Preclinical Phase in progress
|
not started
Clinical Stage Phase 1/2 Phase not started
|
*formerly HM43239
**formerly CG-806
Luxeptinib for B-cell Tumors
Oral, Mutation-Agnostic, Dual Lymphoid / Myeloid Kinase Inhibitor (LKI/MKI)
Luxeptinib is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
View Candidate
Luxeptinib for Myeloid Tumors
Oral, Mutation-Agnostic, Dual Lymphoid / Myeloid Kinase Inhibitor (LKI/MKI)
Luxeptinib is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies.
View Candidate
Tuspetinib (HM43239) for Myeloid Tumors
Oral, Potent Myeloid Kinase Inhibitor (MKI)
Tuspetinib (HM43239) is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).
View Candidate
Posters & Presentations
Our online library includes numerous publications, including presentations, posters, and other media that provide additional information on preclinical and clinical studies of our drug candidates.
View Posters & Presentations